JP2004536558A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536558A5
JP2004536558A5 JP2002545129A JP2002545129A JP2004536558A5 JP 2004536558 A5 JP2004536558 A5 JP 2004536558A5 JP 2002545129 A JP2002545129 A JP 2002545129A JP 2002545129 A JP2002545129 A JP 2002545129A JP 2004536558 A5 JP2004536558 A5 JP 2004536558A5
Authority
JP
Japan
Prior art keywords
src
antisense compound
expression
human
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002545129A
Other languages
Japanese (ja)
Other versions
JP2004536558A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/044220 external-priority patent/WO2002042423A2/en
Publication of JP2004536558A publication Critical patent/JP2004536558A/en
Publication of JP2004536558A5 publication Critical patent/JP2004536558A5/ja
Withdrawn legal-status Critical Current

Links

Claims (5)

ヒトSRC-2をコードする核酸分子を標的とする長さ8〜30の核塩基のアンチセンス化合物であって、ヒトSRC-2に特異的にハイブリダイズし、そしてその発現を阻害する、前記アンチセンス化合物。  An antisense compound of length 8-30 nucleobase targeting a nucleic acid molecule encoding human SRC-2, which specifically hybridizes to human SRC-2 and inhibits its expression Sense compound. アンチセンスオリゴヌクレオチドである、請求項1に記載のアンチセンス化合物。  The antisense compound according to claim 1, which is an antisense oligonucleotide. 請求項1に記載のアンチセンス化合物および医薬的に許容可能な担体または希釈剤を含む、医薬組成物。  A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent. ヒト細胞または組織においてSRC-2の発現を阻害する方法であって、前記細胞または組織と請求項1に記載のアンチセンス化合物とを接触させ、それによりSRC-2の発現を阻害することを含む、前記方法。  A method of inhibiting the expression of SRC-2 in a human cell or tissue, comprising contacting the cell or tissue with the antisense compound of claim 1, thereby inhibiting the expression of SRC-2 , Said method. SRC-2の発現を阻害することによりSRC-2と関連する疾患または症状を有するヒトを治療するための、治療的または予防的有効量の請求項1に記載のアンチセンス化合物を含む、医薬組成物。  A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the antisense compound of claim 1 for treating a human having a disease or condition associated with SRC-2 by inhibiting the expression of SRC-2 object.
JP2002545129A 2000-11-27 2001-11-26 Antisense modulation of SRC-2 expression Withdrawn JP2004536558A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72353000A 2000-11-27 2000-11-27
PCT/US2001/044220 WO2002042423A2 (en) 2000-11-27 2001-11-26 Antisense modulation of src-2 expression

Publications (2)

Publication Number Publication Date
JP2004536558A JP2004536558A (en) 2004-12-09
JP2004536558A5 true JP2004536558A5 (en) 2005-05-19

Family

ID=24906651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002545129A Withdrawn JP2004536558A (en) 2000-11-27 2001-11-26 Antisense modulation of SRC-2 expression

Country Status (4)

Country Link
EP (1) EP1343913A2 (en)
JP (1) JP2004536558A (en)
AU (1) AU2002237678A1 (en)
WO (1) WO2002042423A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8142198A (en) * 1997-06-12 1998-12-30 Regents Of The University Of California, The A transcription factor coactivator protein, p/cip

Similar Documents

Publication Publication Date Title
CA2520541A1 (en) Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
JP2003503454A5 (en)
JP2009513604A5 (en)
JP2004509619A5 (en)
JP2008513510A5 (en)
JP2009508527A5 (en)
JP2009500045A5 (en)
JP2004534850A5 (en)
CO6241169A2 (en) METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
JP2007504269A5 (en)
EP2251007A3 (en) Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
JP2002541233A5 (en)
JP2011528713A5 (en)
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
FI3782612T3 (en) Oral formulations of cytidine analogs and methods of use thereof
JP2008528761A5 (en)
JP2005237328A5 (en)
JP2010500284A5 (en)
WO2003101394A3 (en) Defensins: use as antiviral agents
JP2008521927A5 (en)
JP2004503232A5 (en)
WO2010008474A3 (en) Methods for treating multiple sclerosis using antisense oligonucleotides
JP2009511426A5 (en)
JP2010537958A5 (en)